Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Payables: 2015-2024

Historic Payables for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $4.1 million.

  • Seres Therapeutics' Payables fell 79.68% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 53.82%. This contributed to the annual value of $4.1 million for FY2024, which is 12.03% up from last year.
  • Seres Therapeutics' Payables amounted to $4.1 million in FY2024, which was up 12.03% from $3.6 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Payables registered a high of $17.9 million during FY2022, and its lowest value of $3.6 million during FY2023.
  • In the last 3 years, Seres Therapeutics' Payables had a median value of $4.1 million in 2024 and averaged $8.5 million.
  • As far as peak fluctuations go, Seres Therapeutics' Payables soared by 207.13% in 2021, and later crashed by 79.65% in 2023.
  • Yearly analysis of 5 years shows Seres Therapeutics' Payables stood at $4.5 million in 2020, then skyrocketed by 207.13% to $13.7 million in 2021, then skyrocketed by 30.29% to $17.9 million in 2022, then plummeted by 79.65% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024.